| 1 Blood pressure support (modest) |
Commonly 1 capsule/day; 4–12 weeks (varies by extract and study design) |
Across randomized trials, pomegranate products (juice/extract) are associated with modest average reductions in systolic and diastolic blood pressure, with substantial between-study variability. In one double-blind RCT of pomegranate extract capsules (8 weeks), diastolic BP decreased significantly vs placebo. |
PubMed (2024 meta-analysis)
Cambridge (double-blind RCT) |
| 2 Cardiometabolic markers (mixed) |
Varies widely (juice/extract); typically weeks to months |
Clinical studies report improvements in some endpoints (e.g., triglycerides, LDL/total cholesterol, glycemia/insulin resistance) in some settings, but findings are inconsistent and likely sensitive to dose, extract profile, and baseline risk. |
MDPI (systematic review) |
| 3 Skin appearance (early evidence) |
Standardized extract daily for 4 weeks (75 mg punicalagin per capsule) |
A small randomized, double-blind, placebo-controlled study reported improvements in image-based facial wrinkle severity after 4 weeks of standardized pomegranate extract supplementation. |
MDPI (RCT) |
| 4 Gut microbiome / urolithins (biomarker-driven) |
Varies by extract; response depends on microbiome “metabotype” |
Ellagitannins/ellagic acid can be converted by gut microbes into urolithins (e.g., urolithin A), but individuals differ markedly. A human study in overweight/obese adults reported microbiome and gut-metabolite shifts linked to urolithin A production. |
RSC Food & Function |
